Therapeutic agents useful for treating pain

Details Therapeutic agents useful for treating pain Therapeutic agents useful for treating pain

2006-11-16

2010-06-15

Balasubramanian, Venkataraman (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C544S360000

Reexamination Certificate

active

07737148

ABSTRACT:
A compound of formula:wherein Ar, Ar1, Ar2, R3-R6, R13, m, and t are disclosed herein, or a pharmaceutically acceptable salt thereof (a “Hydroxyiminopiperazine Compound”); compositions comprising an effective amount of a Hydroxyiminopiperazine Compound; and methods for treating or preventing pain and other conditions in an animal comprising administering to an animal in need thereof an effective amount of a Hydroxyiminopiperazine Compound are disclosed.

REFERENCES:
patent: 4439606 (1984-03-01), De et al.
patent: 4450272 (1984-05-01), Du et al.
patent: 5039680 (1991-08-01), Imperato et al.
patent: 5075341 (1991-12-01), Mendelson et al.
patent: 5198459 (1993-03-01), Imperato et al.
patent: 5232934 (1993-08-01), Downs
patent: 5430033 (1995-07-01), Cliffe et al.
patent: 5442064 (1995-08-01), Pieper et al.
patent: 5461047 (1995-10-01), Hansen, Jr. et al.
patent: 5556837 (1996-09-01), Nestler et al.
patent: 5556838 (1996-09-01), Mayer et al.
patent: 5574052 (1996-11-01), Rose et al.
patent: 5756504 (1998-05-01), Bock et al.
patent: 5762925 (1998-06-01), Sagen
patent: 5789412 (1998-08-01), Halazy et al.
patent: 5792768 (1998-08-01), Kulagowski et al.
patent: 6028195 (2000-02-01), Cho et al.
patent: 6109269 (2000-08-01), Rise et al.
patent: 6204284 (2001-03-01), Beer et al.
patent: 6329395 (2001-12-01), Dugar et al.
patent: 6423716 (2002-07-01), Matsuno et al.
patent: 7157462 (2007-01-01), Sun et al.
patent: 7279493 (2007-10-01), Kyle et al.
patent: 7572812 (2009-08-01), Sun et al.
patent: 2003/0092910 (2003-05-01), Cho et al.
patent: 2003/0153596 (2003-08-01), Suh et al.
patent: 2003/0158188 (2003-08-01), Lee et al.
patent: 2003/0158198 (2003-08-01), Lee et al.
patent: 2006/0128717 (2006-06-01), Sun et al.
patent: 2007/0032500 (2007-02-01), Sun et al.
patent: 2008/0153835 (2008-06-01), Kyle et al.
patent: 2009/0042902 (2009-02-01), Sun et al.
patent: 1 122 242 (2001-08-01), None
patent: WO 96/21648 (1996-07-01), None
patent: WO 98/00402 (1998-01-01), None
patent: WO 99/07672 (1999-01-01), None
patent: WO 00/52001 (2000-09-01), None
patent: WO 02/05819 (2002-01-01), None
patent: WO 02/16318 (2002-02-01), None
patent: WO 03/022809 (2003-03-01), None
patent: WO 03/062209 (2003-07-01), None
patent: WO 03/068749 (2003-08-01), None
Valenzano et al. Curr. Med. Chem. 3185-3202, 2004.
Szallasi et al, Journal of Medicinal Chemistry 47(20): 2717-2723, 2004.
Bartho et al., 1990, “Involvement of capsaicin-sensitive neurones in hyperalgesia and enhanced opiod antinociception in inflammation.” Naunyn-Schmiedeberg's Arch Pharmacol. 342:666-670.
Berkow et al., The Merck Manual of Medical Information 1997; 525-526.
Berkow et al., The Merck Manual of Medical Information 1997; 528-530.
Berkow et al., The Merck Manual of Medical Information 1997; 530-532.
Berkow et al., The Merck Manual of Medical Information 1997; 631-634.
Berkow et al., The Merck Manual of Medical Information 1997;345-350.
Berkow et al., The Merck Manual of Medical Information 1997;352-355.
Berkow et al., The Merck Manual of Medical Information 1997;496-500.
Bevan et al., “Vanilloid Receptors: Pivotal Molecules in Nocciception,”Current Opinions in CPNS Investigational Drugs, 2(2):178-85 (2000).
Chiamulera et al., “Reinforcing and Locomotor Stimulant Effects of Cocaine are Absent in mGluR5 Null Mutant Mice,” Nat Neuroscie 2001;4(9):873-874.
Cooke, “Glycopyrrolate in Bladder Dysfunction,” S Afr Med J 1983;63:3.
D'Amour et al., 1941, “A method for Determining Loss of Pain Sensation.” J. Pharamcol. Exp. Ther. 72:74-79.
Di Marzo et al., “Endovanilloid Signaling in Pain,” Curr Opin Neurobiol 2002;12:372-379.
Dogrul et al., Peripheral and Spinal Antihyperalgesic Activity of SIB-1757, a Metabotropic Glutamate Receptor (mGluR5) Antagonist, In Experimental Neuropathic Pain in Rats, Neurosci Lett 2000;292(2):115-118.
Foley, “Pain” Cecil Textbook of Medicine 1996;100-107.
Fundytus et al., “Antisense Oligonucleotide Knockdown of mGluR1Alleviates Hyperalgesia and Allodynia Associated with Chronic Inflammation,” Pharmacol Biochem Behav 2002;73:401-410.
Fundytus et al., “In Vivo Antinociceptive Activity of Anti-rat mGluR1and mGluR5Antibodies in Rats,” NeuroReport 1998;9:731-735.
Fundytus et al., “Knockdown of Spinal Metabotropic Glutamate Receptor 1 (mGluR1) Alleviates Pain and Restores Opioid Efficacy After Nerve Injury in Rats,” Br J Pharmacol 2001;132:354-367.
Fundytus, “Glutamate Receptors and Nociception Implications for the Drug-Treatment of Pain,” CNS Drugs 2001;15:29-58.
Goodman and Gillman's The Pharmaceutical Basis of Therapeutics 506. 901-915 (J. Hardman and L. Limbird eds., 9thed. 1996).
Herzog et al., “Urinary Incontinence: Medical and Psychosocial Aspects,” Annu Rev Gerontol Geriatr 1989;9:74-119.
Kwak et al., “A Capsaicin-Receptor Antagonist, Capsazepine Reduces Inflammation-Induced Hyperalgesic Responses in the Rat: Evidence for an Endogenous Capsaicin-Like Substance,” Neuroscience 1998;84:619-626.
Levin et al., “Direct Measurement of the Anticholinergic Activity of a Series of Pharmacological Compounds on the Canine and Rabbit Urinary Bladder,” J Urol 1982;128:396-398.
Lopez-Rodriquez et al., “VRI Receptor Modulators as Potential Drugs for Neuropathic Pain.”Mini-Revs in Medicinal Chem. 3(7):729-48 (2003).
Mirakhur et al., “Glycopyrrolate: Pharmacology and Clinical Use,” Anaesthesia 1983;38:1195-1204.
Ohkubo et al., “The Selective Capsaicin Antagonist Capsazepine Abolishes the Antinociceptive Action of Eugenol and Guaiacol,” J. Dent Res Apr. 1997;76(4):848-851.
Ossowska et al., “Blockade of the Metabotropic Glutamate Receptor Subtype 5 (mGluR5) Produces Antiparkinsonian-like Effects in Rats,” Neuropharmacology 2001;41:413-420.
Pan et al., “Soluble Polymer-Supported Synthesis of Arylpiperazines,” Tett Lett 1998;39:9505-9508.
Pomonis et al., “N-(4-Tertiarybutylphenyl)-4-(3-chlorophyridin-2-yl)tetrahydropyrazine-1(2H)-carbox-amide (BCTC), a Novel, Orally Effective Vanilloid Receptor 1 Antagonist with Analgesic Properties: II. In Vivo Characterization in Rat Models of Inflammatory and Neuropathic Pain.”J. Pharmacol. Exper. Therapeutics306(1):387-393 (2003).
Resnick, “Urinary Incontinence,” Lancet 1995;346:94-99.
Seltzer et al., 1990, “A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury.” Pain 43:210-215.
Spooren et al., “Novel Allosteric Antagonists Shed Light on mGluR5Receptors and CNS Disorders,” Trends Pharmacol Sci 2001;22(7):331-337.
Szallasi et al., “The Cloned Rat Vanilloid Receptor VRI Mediates Both R-Type Binding and C-Type Calcium Response in Dorsal Root Ganglion Neurons,”Molec. Pharmacol. 56:581-587 (1999).
Szallasi et al., “Vanilloid (Capsaicin) Receptors and Mechanisma.”Pharmacol. Revs., 51(2):159-211 (1999).
Szallasi et al., 2004, “Vanilloid receptor TRPV1 antagonists as the next generation of painkillers. Are we putting the cart before the horse?” J. Med Chem. 47(20):2717-2723.
Tatarczynska et al., “Potential Anxiolytic- and Antidepressant-like Effects of MPEP, a Potent, Selective and Systemically Active mGlu5 Receptor Antagonist,” Br J Pharmacol 2001;132(7):1423-1430.
Urban et al., “In Vivo Pharmacology of SDZ 249-665, A Novel, Non-pungent Capsaicin Analogue,” Pain 2000;89:65-74.
Valenzano et al., 2004, “Current perspectives on the therapeutic utility of VRI antagonists.” Curr. Med. Chem. 3185-3202.
Walker et al., “Metabotropic Glutamate Receptor Subtype 5 (mG1u5) and Nociceptive Function. 1. Selective Blockade of mGlu5 Receptors in Models of Acute, Persistent and Chronic Pain,” Neuropharmacology 2000 40:1-9.
Wang et al., “High Affinity Antagonists of the Vanilloid Receptor,”Mol. Pharmacol. 62(4):947-56 (2002).
Wein, “Pharmac

Affiliated with

Also associated with

Rating

Therapeutic agents useful for treating pain does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Therapeutic agents useful for treating pain, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic agents useful for treating pain will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4240001